SBRT for Early Stage Laryngeal Cancer: Progress, But Not Quite Ready for Prime Time

Cancer of the true glottis has a very low rate of regional metastasis; thus, curative treatment depends on optimized local therapy, with disease-free survival rates in excess of 90%.1 For radiation therapy, the challenge has been enhancing efficacy while preserving or improving the late toxicity of treatment, including effects on voice quality and laryngeal function. As context, hypofractionated radiation therapy (2.25 Gy daily) has been shown to improve local control for early stage glottic cancer compared with daily 2 Gy regimens, with acceptable toxicity of ∼15% to 20% late grade 1 skin or laryngeal effects.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research